An observational study to evaluate the patient characteristics and survival outcomes of lenalidomide with dexamethasone versus bortezomib with dexamethasone post-frontline treatments for multiple myeloma

Trial Profile

An observational study to evaluate the patient characteristics and survival outcomes of lenalidomide with dexamethasone versus bortezomib with dexamethasone post-frontline treatments for multiple myeloma

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2017 Results presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 23 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top